Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-cash Items (2016 - 2023)

Historic Non-cash Items for Editas Medicine (EDIT) over the last 9 years, with Q2 2023 value amounting to $2.6 million.

  • Editas Medicine's Non-cash Items rose 3930.96% to $2.6 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.6 million, marking a year-over-year increase of 3930.96%. This contributed to the annual value of $401.5 million for FY2022, which is 2759184.62% up from last year.
  • According to the latest figures from Q2 2023, Editas Medicine's Non-cash Items is $2.6 million, which was up 3930.96% from $2.2 million recorded in Q1 2023.
  • Editas Medicine's 5-year Non-cash Items high stood at $5.1 billion for Q4 2021, and its period low was $1.3 million during Q2 2021.
  • For the 5-year period, Editas Medicine's Non-cash Items averaged around $625.0 million, with its median value being $16.3 million (2019).
  • As far as peak fluctuations go, Editas Medicine's Non-cash Items surged by 11630140.07% in 2022, and later plummeted by 9994.52% in 2023.
  • Editas Medicine's Non-cash Items (Quarter) stood at $26.1 million in 2019, then surged by 543.28% to $167.6 million in 2020, then skyrocketed by 2913.88% to $5.1 billion in 2021, then crashed by 92.05% to $401.5 million in 2022, then tumbled by 99.36% to $2.6 million in 2023.
  • Its Non-cash Items stands at $2.6 million for Q2 2023, versus $2.2 million for Q1 2023 and $401.5 million for Q4 2022.